AI Support System Spółka z Ograniczoną Odpowiedzialnością (KRS 0000875490, NIP 5170412402) is a Polish company, headquartered in Rzeszów, Podkarpackie voivodeship. AI Support System operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since December 23, 2020. AI Support System's most recently reported net revenue was 700 PLN for 2024.
Negative equity
Negative equity in 1 of 3 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - AI Support System
Identity
- Name
- AI Support System Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 23, 2020
- Registry status as of
- November 29, 2025
- Latest entry
- November 28, 2025
- Founding act
- 26.10.2020 R., REP. A NR 14239/2020, NOTARIUSZ MARIUSZ ŁUKASIK, KANCELARIA NOTARIALNA W KRAKOWIE
Articles of association history (1)
- October 26, 2020: 26.10.2020 R., REP. A NR 14239/2020, NOTARIUSZ MARIUSZ ŁUKASIK, KANCELARIA NOTARIALNA W KRAKOWIE
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- PL. JANA KILIŃSKIEGO, 2, 35-005, RZESZÓW, POLSKA
- Voivodeship
- PODKARPACKIE
- District
- RZESZÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-94791-94157-REDWE-32
Risk and payment profile - AI Support System
Credibility rating
1 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
46
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/5 yrs
Board changes
1
1/5 yrs
PKD changes
0
0/5 yrs
Name changes
1
1/5 yrs
Data from 5 years of registry activity.
Credibility history
Payment reliability score from 2022–2024
Current: E (1/100)
Trend: deteriorating (-37.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2022–2024
Current: 8.33 PLN
Safe: 0.83 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - AI Support System
Founded
December 23, 2020
5 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
RZESZÓW
PODKARPACKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
14.0 K PLN
280 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
3 years
2022–2024 · profitable: 1/3
Registry entries
19
latest: November 28, 2025
Risk signals
Revenue
700 PLN
2024
Net profit
-97.9 K PLN
2024
Assets
6.0 K PLN
2024
Equity
-668.1 PLN
2024
EBITDA
369.0 K PLN
2024
Valuation
1.0 M PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - AI Support System.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
